Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infigratinib in children with achondroplasia
NCT04265651Phase 2Completed
- Sponsor
- QED Therapeutics
- Start
- Mar 2020
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of infigratinib in achondroplasia (ACH), sponsored by QED Therapeutics. Started Mar 2020; status: completed.
02
Drugs
infigratinib
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT04265651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04265651.